Fifty years ago, clinical pharmacologist Harry Shirkey noted that children are often “therapeutic orphans” in biomedical research — a trend that continues, with pediatric biomedical advances lagging behind those for adults, and rare pediatric-only conditions, or “orphan diseases,” lacking a market sufficient to drive intervention. …